Evidence map›Paper›PMID 41408564›Full record

ArticleJournal of translational medicine2025

Molecular subtyping and prognostic evaluation in idiopathic pulmonary fibrosis: a focus on mechanical-related genes.

Zibin Chen, Yupeng Zhi, Bo Wu, Hongzhao Huang, Mingwei Zhang, Jinsheng Hong, Yansong Guo, Chun Chen

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Transcriptomic Association of COL3A1Pain research & management · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zibin Chen *School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, 350122, China.
Yupeng Zhi *School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, 350122, China.
Bo WuDepartment of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 361000, China.
Hongzhao HuangSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian, 350122, China.
Mingwei ZhangDepartment of Radiotherapy, Cancer Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, China. zhangmingwei28@sina.cn.
Jinsheng HongDepartment of Radiotherapy, Cancer Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, China. 13799375732@fjmu.edu.cn.
Yansong GuoDepartment of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, 350001, China. ysguo1234@126.com.
Chun ChenSchool of Pharmacy, Fujian Medical University, Fuzhou, Fujian, 350122, China. chenchun-0428@fjmu.edu.cn.ORCID 0000-0003-0404-3094

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIdiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by fibroblast activation and extracellular matrix deposition. Although mechanical forces are known to influence critical processes such as tissue remodeling and cellular differentiation, the specific role of mechanosensitive genes in IPF pathogenesis remains poorly understood.

methodsThis study applied mechanical force-related scoring to IPF and control samples. Weighted Gene Co-expression Network Analysis (WGCNA) was used to identify IPF-specific genes associated with mechanical force-related scores, which were subsequently subjected to enrichment analysis. Core genes were screened through univariate Cox regression analysis and machine learning algorithms. Independent prognostic genes were determined using stepwise multivariate Cox regression analysis, which informed the construction of a nomogram integrating key clinicopathological variables. The core genes were further analyzed through single-cell RNA sequencing (scRNA-seq) and Connectivity Map (CMap) analyses to investigate molecular subtypes and identify potential therapeutic targets.

resultsIPF samples exhibited significantly higher scores related to mechanical-related genes (MRGs). Moreover, these samples demonstrated notable heterogeneity, with distinct patterns of high and low mechanical force-associated scores. Core gene analysis revealed two distinct molecular subtypes among idiopathic IPF samples. The C2 subtype was characterized by pronounced inflammatory responses, activation of mechanotransduction pathways, and more severe pathological features. CMap analysis identified nifekalant, which targets AGTR2, as a potential therapeutic agent for the C2 subtype. CD24, PPP1R14C, DSP, and CC2D2A were identified as diagnostic biomarkers, among which CD24, PPP1R14C, and CC2D2A also served as independent prognostic indicators. scRNA-seq demonstrated elevated expression of CD24 and CC2D2A in IPF samples, predominantly within ciliated cells. Pseudotime trajectory analysis revealed two distinct cell fate trajectories in IPF samples. Differentiation toward cell fate 1 was associated with enhanced protein synthesis and secretion, whereas cell fate 2 and the branching point origin region exhibited increased cell adhesion and activation of the p38 MAPK signaling pathway.

conclusionCD24, PPP1R14C, and CC2D2A were identified as prognostic genes associated with MRGs, functioning as markers for molecular subtyping in IPF. These genes may contribute to the pathogenesis of IPF by modulating mechanotransduction processes within epithelial cell subpopulations.

Indexed as

Idiopathic Pulmonary FibrosisAgedFemaleGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksHumansMaleMiddle AgedPrognosisIdiopathic pulmonary fibrosisMachine learningMechanical-related genesMolecular subtypePrognostic evaluationSingle-cell sequencing

Identifiers

PMID41408564
PMCPMC12709814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.